Product Details
Quinsair
Levofloxacin240 mg/2.4 mL (100 mg/mL)
Solution for Inhalation
Single-Use 2.4-mL Ampoule (Preservative Free)
DIN/PIN/NPN
02442302
Manufacturer
Horizon Therapeutics Ireland DAC
Formulary Listing Date
2019-02-04
Unit Price
64.4887
Amount MOH Pays
64.4887
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
J01MA12
Interchangeable Products
NOLU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Anti-Infectives | Levofloxacin hemihydrate
For the management of adult cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections who meet the following criteria:
Exclusion criteria:
Approval duration: 1 year Renewal requests: Patient demonstrates response to therapy. |